Alessio Terenzi published in the Journal Dalton Transactions: "Self-assembled Pt2L2 boxes strongly bind G-quadruplex DNA and influence gene expression in cancer cells" pubs.rsc.org/en/Content/ArticleLanding/2017/DT/C6DT03876J
Furthermore, Alessio Terenzi was awarded the front cover of the first issue of Dalton Transaction in 2017: pubs.rsc.org/en/content/articlepdf/2017/dt/c7dt90006f
Mohamed Elgendy (http://indicar.univie.ac.at/fellows/elgendy-mohamed/) just published an article in the Journal of Clinical Investigation (Impact Factor 13.2): "Dual modulation of MCL-1 and mTOR determines the response to sunitinib" https://www.jci.org/articles/view/84386
"In brief, the paper unravels mechanisms by which tumors adapt to and resist a drug called Sunitinib that's the first line therapy (best option) for renal cancer, making almost all the patients treated with this drug relapse within months. We also identified a clinical approach to make those tumors sensitive to this drug and potentially expand the lifespan of those patients."
This publication was also featured in one of the biggest newspapers in Italy: http://www.repubblica.it/salute/2016/11/28/news/tumori_resistenza_ai_farmaci_ieo-153021807/
Our INDICAR fellow Alessio Terenzi just published the paper "Another step toward DNA selective targeting: NiII and CuII complexes of a Schiff base ligand able to bind gene promoter G-quadruplexes" in Dalton Transactions.
Abstract: DNA G-rich sequences are able to form four-stranded structures organized in stacked guanine tetrads. These structures, called G-quadruplexes, were found to have an important role in the regulation of oncogenes expression and became, for such a reason, appealing targets for anticancer drugs. Aiming at finding selective G-quadruplex binders, we have designed, synthesized and characterized a new water soluble Salen-like Schiff base ligand and its NiII and CuII metal complexes. UV-Vis, circular dichroism and FRET measurements indicated that the nickel complex can stabilize oncogene promoter G-quadruplexes with high selectivity, presenting no interactions with duplex DNA at all. The same compound exhibited dose-dependent cytotoxic activity in MCF-7 breast cancer cells when combined with lipofectamine as lipophilic carrier.